Skoumalova Ivana, Vondrakova Jana, Rohon Peter, Rozmanova Sarka, Jarosova Marie, Indrak Karel, Prochazka Martin, Santava Alena, Faber Edgar
Department of Hemato-Oncology, Teaching Hospital Olomouc, Czech Republic.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008 Jun;152(1):121-3. doi: 10.5507/bp.2008.019.
To report a case of successful pregnancy in a patient with chronic myelogenous leukemia treated with imatinib mesylate for the first 4 months of pregnancy.
Imatinib mesylate is potentially teratogenic and its use during pregnancy in humans can lead to abortion or development of fetal abnormalities in nearly 40% of fully reported cases. We report a case of a 28-year-old woman who delivered a healthy child of normal weight after having been treated with imatinib for Ph1-positive CML during the first four months of her pregnancy. She refused advocated interruption and for the rest of the pregnancy was treated with interferon. The treatment was associated with a rapid 2-log increase in the leukemia clone measured by the real-time polymerase chain reaction. Reintroduction of imatinib after delivery resulted in achievement of the complete cytogenetic response again.
We discuss possible strategies for successful management of pregnancy in CML patients treated with imatinib.
报告一例慢性髓性白血病患者在妊娠前4个月接受甲磺酸伊马替尼治疗后成功妊娠的病例。
甲磺酸伊马替尼具有潜在致畸性，在人类妊娠期间使用，在几乎40%的完整报告病例中可导致流产或胎儿异常发育。我们报告一例28岁女性病例，她在妊娠前4个月因Ph1阳性慢性髓性白血病接受伊马替尼治疗后，产下一名体重正常的健康婴儿。她拒绝了建议的中断妊娠，在妊娠剩余时间接受干扰素治疗。该治疗与通过实时聚合酶链反应测量的白血病克隆快速2个对数增加相关。产后重新使用伊马替尼再次实现了完全细胞遗传学缓解。
我们讨论了伊马替尼治疗的慢性髓性白血病患者成功管理妊娠的可能策略。
